Development of antibody surrogates for the treatment of cancers and autoimmune disease.
Some therapeutic monoclonal antibodies function by focusing the killing power of the immune system on particular cellular targets, a process known as antibody-dependent cell-mediated cytotoxicity (ADCC). There is considerable interest in developing small-molecule therapeutics that utilize this mechanism of action and so act as a kind of antibody surrogate. Progress and challenges in this interesting field are reviewed here.
Kodadek
Thomas
T
Department of Chemistry, The Scripps Research Institute, Scripps Florida, Jupiter, FL 33458, USA. kodadek@scripps.edu
D000818:Animals; D000906:Antibodies / Q000276:immunology* / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology*; D040761:Biomimetic Materials / Q000737:chemistry; D006801:Humans; D008024:Ligands; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology*
D000906:Antibodies; D008024:Ligands